Todd Grinnell

500 total citations
47 papers, 356 citations indexed

About

Todd Grinnell is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Todd Grinnell has authored 47 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Psychiatry and Mental health, 31 papers in Pediatrics, Perinatology and Child Health and 17 papers in Cellular and Molecular Neuroscience. Recurrent topics in Todd Grinnell's work include Epilepsy research and treatment (39 papers), Pharmacological Effects and Toxicity Studies (30 papers) and Neuroscience and Neuropharmacology Research (16 papers). Todd Grinnell is often cited by papers focused on Epilepsy research and treatment (39 papers), Pharmacological Effects and Toxicity Studies (30 papers) and Neuroscience and Neuropharmacology Research (16 papers). Todd Grinnell collaborates with scholars based in United States, Portugal and Germany. Todd Grinnell's co-authors include David Blum, Hailong Cheng, Michael R. Sperling, Jay Harvey, Mercedes Jacobson, Helena Gama, Perminder Bhatia, Holly Huang, Ladislav Pazdera and D. Alan Lankford and has published in prestigious journals such as Neurology, PEDIATRICS and Epilepsia.

In The Last Decade

Todd Grinnell

43 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Todd Grinnell United States 9 302 252 131 49 29 47 356
Gregory S. Carter United States 5 337 1.1× 308 1.2× 109 0.8× 28 0.6× 9 0.3× 9 405
Verena Gaus Germany 8 282 0.9× 197 0.8× 71 0.5× 31 0.6× 14 0.5× 18 365
Christian Samsonsen Norway 7 175 0.6× 139 0.6× 33 0.3× 29 0.6× 10 0.3× 11 227
Steffi Koch‐Stoecker Germany 10 305 1.0× 205 0.8× 85 0.6× 45 0.9× 13 0.4× 13 339
L. Diepman Netherlands 13 495 1.6× 352 1.4× 163 1.2× 148 3.0× 11 0.4× 16 576
Lara Kay Germany 10 281 0.9× 229 0.9× 141 1.1× 29 0.6× 3 0.1× 15 333
Siddhartha Nadkarni United States 8 207 0.7× 107 0.4× 81 0.6× 63 1.3× 13 0.4× 11 341
Mine Özmen Türkiye 11 275 0.9× 56 0.2× 47 0.4× 34 0.7× 38 1.3× 26 442
M. W. Lammers Netherlands 12 144 0.5× 109 0.4× 42 0.3× 36 0.7× 32 1.1× 17 372
Lori Clapp United States 9 111 0.4× 29 0.1× 100 0.8× 63 1.3× 10 0.3× 11 370

Countries citing papers authored by Todd Grinnell

Since Specialization
Citations

This map shows the geographic impact of Todd Grinnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Grinnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Grinnell more than expected).

Fields of papers citing papers by Todd Grinnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Grinnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Grinnell. The network helps show where Todd Grinnell may publish in the future.

Co-authorship network of co-authors of Todd Grinnell

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Grinnell. A scholar is included among the top collaborators of Todd Grinnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Grinnell. Todd Grinnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vieluf, Solveig, Bo Zhang, Vaishnav Krishnan, et al.. (2025). Seizure monitoring by combined diary and wearable data: A multicenter, longitudinal, observational study. Epilepsia. 66(11). 4259–4271.
2.
3.
David-Pereira, Ana, et al.. (2023). Time to sustained responder status in patients with focal seizures treated with adjunctive eslicarbazepine acetate. Epilepsy Research. 198. 107262–107262. 1 indexed citations
4.
Aboumatar, Sami, et al.. (2022). Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial. Clinical Neurology and Neurosurgery. 225. 107552–107552. 3 indexed citations
5.
Davis, Matthew, et al.. (2021). Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs. ClinicoEconomics and Outcomes Research. Volume 13. 251–261. 2 indexed citations
6.
Hixson, John, et al.. (2021). Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. Epilepsy Research. 171. 106561–106561. 9 indexed citations
7.
Andermann, Eva, William E. Rosenfeld, Patricia Penovich, et al.. (2020). Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18–59 years) adults. Epilepsy Research. 169. 106478–106478. 3 indexed citations
8.
9.
Wechsler, Robert, Rodney A. Radtke, Michael C. Smith, et al.. (2019). Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy. Epilepsia. 60(7). 1341–1352. 8 indexed citations
10.
Mintzer, Scott, et al.. (2019). Markers of bone and lipid metabolism with eslicarbazepine acetate monotherapy. Epilepsy Research. 158. 106216–106216. 5 indexed citations
11.
12.
13.
14.
Biton, Victor, Joanne Rogin, Gregory L. Krauss, et al.. (2017). Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials. Epilepsy & Behavior. 72. 127–134. 42 indexed citations
15.
Gidal, Barry E., et al.. (2017). Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. Epilepsy Research. 135. 64–70. 7 indexed citations
16.
17.
Sramek, John J., Larry W. Hardy, P. R. Bieck, et al.. (2016). Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects. CNS Neuroscience & Therapeutics. 22(5). 404–412. 3 indexed citations
18.
19.
Sperling, Michael R., Jay Harvey, David Blum, & Todd Grinnell. (2014). Conversion to Monotherapy with Eslicarbazepine Acetate in Adults with Partial-Onset Seizures - Results of a North-American Study (P3.242). Neurology. 82(10_supplement). 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregory S. Carter Breakdown of academic impact, for papers by Verena Gaus Breakdown of academic impact, for papers by Christian Samsonsen Breakdown of academic impact, for papers by Steffi Koch‐Stoecker Breakdown of academic impact, for papers by L. Diepman Breakdown of academic impact, for papers by Lara Kay Breakdown of academic impact, for papers by Siddhartha Nadkarni Breakdown of academic impact, for papers by Mine Özmen Breakdown of academic impact, for papers by M. W. Lammers Breakdown of academic impact, for papers by Lori Clapp
Rankless by CCL
2026